Or wait…
Sign in Register
Headlines
Brand Innovation
Formulation & Science
Packaging & Design
Business & Financial
Market Trends
Regulation & Safety
Promotional Features
Site Archive
Multimedia
Hot Topics
Clean & Ethical Beauty
Brexit
COVID-19
Protection and Microbiome
Active beauty and nutricosmetics
Animal Testing
Sustainability and circular beauty
Beauty tech and digital
Financial focus
Naturals and organics
Site Archive
Multimedia
Resources
Type of resources
Events
Shows & Conferences
Editorial Webinars
Online Events
All Events
Events
Related Sites
By Kacey Culliney
– Last updated on GMT
Related tags: Beiersdorf, skin microbiome, microbiome, Skin health, Acne, biotech, Skin care, Skin, acquisition
Announced today, the majority stake leads on from Beiersdorf’s earlier investment in S-Biomedic back in 2018 as part of its corporate venture capital activities. Under the latest deal, S-Biomedic would continue to be managed as a standalone entity under Beiersdorf’s existing microbiome programme, complementing existing research activities.
“In the last few years, microbiome research has become one of the spotlight topics in science and offers unique starting points for breakthrough skin care innovations,” said Beiersdorf.
Founded in 2014, S-Biomedic was dedicated to researching the balance of the skin’s microbiome and developing active ingredients for cosmetic products. The company’s technology selected natural probiotic strains able to influence host-microbiome symbiosis and microbiota population stability. Back in February 2020, Dutch specialty ingredients major Royal DSM signed an exclusive agreement with the Belgian startup to develop and commercialise actives using probiotic technology to treat acne.
This was an area Beiersdorf also said its majority stake acquisition would help advance – the field of acne treatment, a condition that occurred when the skin’s natural microbiome was out of balance.
Dr Gitta Neufang, senior VP of R&D at Beiersdorf, said the acquisition was certainly a strategic fit in terms of innovation and skin care research.
“Together with the pioneers of S-Biomedic, we are taking skin care to the next level and will foster the development of solutions for unmet consumer needs,” Neufang said.
Jörn Hendrik Reuter, manager of the Microbiome Accelerator division at Beiersdorf, added: “The advances of S-Biomedic in biomedical research complement our own efforts in this field and open the door to develop products that work in harmony with the natural skin processes.”
Reuter previously discussed his vision for the future of skin microbiome innovation and development during CosmeticsDesign-Europe’s Skin Microbiome webinar last year, which can still be watched in full, on-demand.
Veronika Oudova, CEO of S-Biomedic, said: “Our vision since 2014 when we started S-Biomedic has been to build and promote skin microbiome technologies and make them (…) the new frontier in skin health. I am very excited that together with the team we have achieved a very important milestone on that journey. By joining Beiersdorf, our novel approach has its path to consumers all over the world.”
In October, this year, French-headquartered venture capital firm Seventure Partners said it would invest €300m in more than 20 cutting-edge companies next year, as part of a third wave of microbiome innovation funds – a move its CEO Isabelle Cremoux said aligned with interest and research activity in the field.
“The [microbiome] field has continuously gained momentum, not only in skin care but in all applications. Because, in fact, scientifically, more is being discovered in the microbiome and its role linking the microbiome composition to the immune system of a person, to the general health, and lots of diseases or health conditions,” Cremoux said.
Advances in technology, she said, had certainly driven many breakthroughs in the field thus far, and would likely continue to do so in the near future.
Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Related topics: Business & Financial, Protection and Microbiome, Financial focus, Skin Care
Show more
L-137™ is a heat-treated strain of Lactobacillus plantarum; this Postbiotic ingredient has the unique capability of improving Skin Health from within.
Pycnogenol® has 25+ clinical studies demonstrating its active ingredient properties for oral and topical skincare formulations. Results show the potent...
Lubrizol Xpozuki™ biotech ingredient is on a mission to support the restoration of 1 million hectares of trees throughout the Andes. With every km you...
Green cosmetics are a growing sub-market within the skin care industry and signs point to it only growing in strength.
Show more
On-demand webinars
More promotional features
